GlassScriptPhysician profile
Jamie Lynn Konschnik
NPI 1578089884
$9,431.27
in general payments reported to CMS, 2019-2025
27 companies · $2,182 in 2025
The $2,182 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,333 · 2022: $1,292 · 2023: $1,929 · 2024: $2,695 · 2025: $2,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,773 · Education: $32.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,773.27 |
| Education | $32.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $2,295.41 | 2021-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $1,536.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $741.24 | 2023-2025 | Jardiance |
| Amgen INC. | $642.27 | 2021-2025 | Tavneos, Parsabiv |
| Calliditas Therapeutics US INC. | $604.03 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $406.79 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Daiichi Sankyo INC. | $398.72 | 2021-2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $361.08 | 2021-2025 | Farxiga, Evusheld, Lokelma |
| Glaxosmithkline, LLC. | $353.76 | 2021-2025 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $275.53 | 2021-2024 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $198.44 | 2021-2025 | Velphoro, Korsuva, Velphoro |
| Mallinckrodt Hospital Products INC. | $191.05 | 2021-2024 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $189.83 | 2021-2025 | Jynarque |
| Kyowa Kirin, INC. | $173.11 | 2022-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $161.55 | 2021-2025 | Ultomiris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $154.71 | 2022-2024 | |
| Novo Nordisk INC | $151.11 | 2025 | Ozempic, Rybelsus |
| Nxstage Medical, INC. | $120.34 | 2023 | Nxstage System One |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $76.80 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $66.07 | 2021-2022 | |
| Lilly USA, LLC | $63.73 | 2024 | Jardiance |
| Scpharmaceuticals INC. | $61.07 | 2025 | |
| Novartis Pharmaceuticals Corporation | $55.69 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $53.93 | 2021 | |
| Pfizer INC. | $36.38 | 2023-2024 | |
| Medtronic, INC. | $31.81 | 2022 | |
| Apellis Pharmaceuticals, INC. | $30.77 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Konschnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.